For nonmetastatic breast cancer, endocrine therapy is used mainly for patients with hormone receptor-positive tumors, and a minority of patients also receive chemotherapy [9]; ERBB2-targeted antibody or small-molecule inhibitor therapy, combined with chemotherapy, is used mainly for patients with ERBB2-positive tumors [10]; patients with triple-negative tumors receive chemotherapy alone [10]. Here, ERBB2 is linked to breast carcinoma.